Atea Pharmaceuticals

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atea Pharmaceuticals advances COVID-19 treatment, diversifies programs for growth

Atea Pharmaceuticals showcased strong performance in clinical development and financial stability, with a focus on addressing COVID-19 therapy limitations.
While challenges exist in deprioritizing the Dengue program, opportunities in other antiviral programs and strategic shifts offer avenues for growth.
The company's extended cash guidance to 2026 reflects adaptability to changing priorities and a commitment to long-term success.

Atea Pharmaceuticals excels in Q1 2023, poised for growth

Atea Pharmaceuticals demonstrated strong financial performance and progress in their COVID-19 and HCV programs in Q1 2023.
The company's robust cash balance, operational excellence, and promising drug profiles highlight their competitive position.
While facing challenges in regulatory environments and clinical trial execution, Atea has opportunities for growth and market expansion.
Overall, Atea Pharmaceuticals remains well-positioned for future success with a focus on innovation and strategic partnerships.

Atea Pharmaceuticals reports strong Q2 earnings, eyes growth in antiviral treatments

Atea Pharmaceuticals demonstrated financial stability and progress in their antiviral programs, particularly in COVID-19 and hepatitis C treatments. While challenges with COVID-19 mutations persist, the company's focus on innovative treatments and potential partnerships signal a promising future in the antiviral market.

Atea Pharmaceuticals excels in antiviral programs, eyes multibillion-dollar market

Atea Pharmaceuticals demonstrated strong performance in Q3 2023, leveraging their expertise in antiviral therapeutics to address critical healthcare challenges. While challenges such as trial enrollment and market competition exist, the company is well-positioned to capitalize on the growing demand for innovative antiviral treatments.

Atea Pharmaceuticals excels in drug development, eyes growth opportunities

Atea Pharmaceuticals is making significant strides in drug development, particularly in COVID-19 and HCV programs. With a strong financial position and a focus on addressing unmet medical needs, the company is poised for future growth and success.

Atea Pharmaceuticals reports robust Q1 earnings, highlights bemnifosbuvir potential

Atea Pharmaceuticals showcased strong financial stability and promising developments in its COVID-19 and HCV programs during the Q1 2024 earnings call. While facing challenges in trial enrollments and regulatory pathways, the company remains well-positioned to capitalize on market opportunities and deliver value through innovative treatments.

Atea Pharmaceuticals reports strong Q2 earnings and advances HCV treatments

Atea Pharmaceuticals is well-positioned with strong operational performance, a promising HCV treatment pipeline, and a solid financial foundation. Navigating industry competition and successfully advancing Phase III trials will be key challenges, but the company has opportunities to solidify its position as a leader in HCV treatment.

Atea Pharmaceuticals excels in Q3 with promising HCV program

Atea Pharmaceuticals demonstrated strong performance in Q3 2024, with promising trial results and a solid financial position.
The company's HCV program shows great potential for addressing unmet medical needs and driving future growth.
While facing challenges in trial design and market competition, Atea remains confident in its ability to innovate and succeed in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allegro MicroSystems

Biodesix

Gatos Silver

Galecto

Leslie's

Lufax Holding

MediaAlpha

Root

SQZ Biotechnologies

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 million at a $4.4 billion market cap.

U.S. IPO Week Ahead: The IPO Market Takes A Break During The Shortened Holiday Week

Experienced Financial Executive Brings Leadership and Public Company Expertise Experienced Financial Executive Brings Leadership and Public Company Expertise

Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan

Full Exercise of the Underwriters' Overallotment Brings Additional $45 Million Full Exercise of the Underwriters' Overallotment Brings Additional $45 Million

Atea Pharmaceuticals Announces Closing of Initial Public Offering

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a price to the public of $24.00 per share. All of the shares of common stock are being offered by Atea. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Atea, are expected to be $300 million, excluding any exercise of the underwriters' option to purchase additional shares. Atea's common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “AVIR” on October 30, 2020. The offering is expected to close on November 3, 2020, subject to satisfaction of customary closing conditions. In addition, Atea has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of Atea's common stock at the initial public offering price less the underwriting discounts and commissions.

Atea Pharmaceuticals Announces Pricing of Initial Public Offering

Atea Pharmaceuticals intends to raise $253 million in a U.S. IPO of its common stock. The firm is developing treatments for virus-borne diseases such as Covid-19 and Hepatitis C.

Atea Pharmaceuticals Proposes Terms For $253 Million IPO

Atea Pharma has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering.

Atea Pharma Announces Potential Pricing for IPO

Atea Pharmaceuticals Inc., a clinical-stage biotech that specializes in anti-viral therapies, set terms for its initial public offering on Monday with plans to offer 11 million shares priced at $22 to $24 each. The company has applied to list on Nasdaq, under the ticker "AVIR.

Atea Pharmaceuticals to offer 11 million shares in IPO, priced at $22 to $24 each

News for Atea Pharmaceuticals Stock (AVIR)